Chemical Component Summary

NameL-CAPTOPRIL
Identifiers(2S)-1-[(2S)-2-methyl-3-sulfanyl-propanoyl]pyrrolidine-2-carboxylic acid
FormulaC9 H15 N O3 S
Molecular Weight217.28
TypeNON-POLYMER
Isomeric SMILESC[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
InChIInChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
InChIKeyFAKRSMQSSFJEIM-RQJHMYQMSA-N

Chemical Details

Formal Charge0
Atom Count29
Chiral Atom Count2
Bond Count29
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB01197 
NameCaptopril
Groupsapproved
DescriptionCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Synonyms
  • Captoprilum
  • Captopryl
  • L-Captopril
  • (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
  • D-3-mercapto-2-methylpropanoyl-L-proline
Brand Names
  • Ratio-captopril Tab 25mg
  • Dom-captopril
  • Nu-capto Tab 25mg
  • Tria-captopril 50mg Tablet
  • Captopril-12.5 Tab 12.5mg
IndicationFor the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Categories
  • ACE Inhibitors and Diuretics
  • Acids, Acyclic
  • Agents Acting on the Renin-Angiotensin System
  • Agents causing angioedema
  • Agents causing hyperkalemia
ATC-Code
  • C09AA01
  • C09BA01
CAS number62571-86-2

Drug Targets

NameTarget SequencePharmacological ActionActions
Angiotensin-converting enzymeMGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFA...unknowninhibitor
72 kDa type IV collagenaseMEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELA...unknowninhibitor
Matrix metalloproteinase-9MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY...unknowninhibitor
Leukotriene A-4 hydrolaseMPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNL...unknowninhibitor
B1 bradykinin receptorMASSWPPLELQSSNQSQLFPQNATACDNAPEAWDLLHRVLPTFIISICFF...unknown
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682